Ikonisys Announces First Sale of Ikoniscope20 Solution Including Newly Added Complete Urology Reagents

PARIS–(BUSINESS WIRE)–Regulatory news:

Ikonisys SA (ISIN Code: FR00140048X2 / Mnemonic: ALIKO) (Paris:ALIKO), a company specializing in the early and accurate detection of cancer with a unique fully automated solution for medical diagnostic laboratories, announces the first sale of a digital microscope solution Ikoniscope20 fluorescence with its optimized reagents.

As announced during Ikonisys’ IPO, the initial goal of the US go-to-market strategy is to convert current customers into Ikoniscope20 users. Active user of the old Ikoniscope Gen1 platform from Ikonisys until today, Comprehensive Urology decided to upgrade its system to the Ikoniscope20 and at the same time use the optimized reagents provided by Ikonisys to perform its diagnosis. molecule of bladder cancer.

Ikonisys’ business model is to sell a fully integrated solution including hardware, software and consumables. Reagents, required to perform each test, are an essential part of the molecular diagnostics market. Ikonisys offers its customers optimized reagents at a competitive price, guaranteeing better performance with the ikoniscope20.

The Ikoniscope20 combined with Ikonisys FISH probes will automate the early diagnosis of bladder cancer, enabling Comprehensive Urology to perform several thousand tests per year.

Manny Iglesias, Ikonisys USA Commercial Directorsaid: “We are very pleased with this sale to Comprehensive Urology, a very reputable, long-time customer who has decided to migrate to the state-of-the-art Ikoniscope20. We anticipate this will pave the way for further sales and thereby accelerate our business activities in the United States and North American markets. »

Jurgen Schipper, Commercial Director of Ikonisys, added: “This sale not only confirms the feasibility of our business model, but also demonstrates our commercial traction. We are very confident in our business model and in the effectiveness of our solution. As announced during the IPO, our strategy is to reach out to KOLs first, demonstrating the effectiveness of our platform and leveraging word of mouth, which is spreading rapidly in our industry.

Issam Atoussi Director of Integral Urology Operations added“We have been using the Ikoniscope Gen1 technology for about 12 years now and are more than satisfied with the results. Upgrading to the Ikoniscope20 will improve performance, and Ikonisys’ reagents ensure we make full use of its capabilities providing the most accurate and comprehensive results for our patients.

About Ikonisys

Ikonisys SA is a cell diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specializing in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20® platform, a fully automated solution designed to provide accurate and reliable detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. With its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on circulating tumor cells (CTCs).

For more information, visit www.Ikonisys.com

About Comprehensive Urology

Comprehensive Urology is committed to providing convenient, timely, and cost-effective urology care by applying best practice protocols and state-of-the-art technology.

The group has more than 50 urologists spread across southeast Michigan, with 30 offices conveniently located to serve its patients.

Doctors specializing in urology have published more than 1,000 articles in peer-reviewed publications and also participated in hundreds of urological presentations in more than 20 foreign countries.

Each year, the group tops the Top Docs in Hour magazine list, with more doctors chosen than any other group in the state.


This press release contains forward-looking statements about the prospects and development of the Company. These statements are sometimes identified by the use of the future, conditional and forward-looking words such as “believe”, “aim”, “expect”, “intend”, “estimate”, “believe”. “, “should”, “could”, “will” or “will” or, where applicable, the negative form of these terms or any other variation or similar expression. This information is not historical data and should not be interpreted as a guarantee that the facts and data stated will occur. This information is based on data, assumptions and estimates considered reasonable by the Company. It is subject to change or change due to uncertainties related to the environment economic, financial, competitive and regulatory This information contains data relating to the intentions, estimates and objectives of the Company concerning in particular the market, strategy, growth, results, financial situation and Company cash. The forward-looking information contained in this press release speaks only as of the date of this press release. The Company does not undertake to update the forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all the risks, uncertainties or other factors that could affect its business, their potential impact on its business or the extent to which the materialization of a risk or a combination of risks could cause results to differ materially from those expressed in any forward-looking information, it being remembered that none of this forward-looking information constitutes a guarantee of actual results.

Laura J. Boyer